VSee Health Registers Resale of 3.54M Shares Under $5M Strata Equity Line

summarizeSummary

VSee Health registered the resale of up to 3.54 million shares by ClearThink under a $5M equity line, with shares purchasable at an 85% discount to market. If fully drawn, outstanding shares would increase more than five-fold from 806,078 to 4.31 million.

check_boxKey Events · Financing and Capital Events · VSEED

• Resale Registration for 3.54M Shares

  S-1 registers resale of up to 3,540,000 shares by ClearThink Capital Partners, consisting of 40,000 commitment fee shares and up to 3,500,000 shares issuable under the Strata Agreement.

• Deeply Discounted Purchase Price

  ClearThink may purchase shares at 85% of the lowest daily closing price during the ten trading days preceding each purchase, a 15% discount to the lowest recent price.

• Potential Five-Fold Share Increase

  If all 3,500,000 shares are issued, outstanding common stock would rise from 806,078 to 4,306,078 shares, a more than five-fold increase.

• No Proceeds from Resale

  The company receives no proceeds from ClearThink's resales; any proceeds from its own sales to ClearThink are earmarked for working capital and general corporate purposes.

auto_awesomeAnalysis · VSEED · Industrial Applications And Services

VSee Health filed an S-1 to register the resale of up to 3,540,000 shares by ClearThink Capital Partners under a $5.0 million equity purchase agreement signed September 2, 2026. The company may sell up to 3,500,000 shares to ClearThink at an 85% discount to the lowest closing price over the prior ten trading days, with 40,000 commitment fee shares already issued. If all 3,500,000 shares are issued, outstanding shares would rise from 806,078 to 4,306,078 — a more than five-fold increase. The company receives no proceeds from ClearThink's resales, but may receive working capital from its own sales to ClearThink. This registration comes just days after a 1-for-80 reverse stock split and follows a series of distressed convertible note financings, including a $180,550 draw from Vanquish on September 24, 2026. The deeply discounted purchase price and the scale of potential issuance relative to the current share count make this a highly dilutive financing arrangement for existing holders.